Methods of treating charcot-marie-tooth disease
A method of treating Charcot Marie Tooth Disease in a human in need thereof. The method comprises systemically administering to the human a non-antibacterial tetracycline compound or antibacterial tetracycline compound, in an amount that is effective to treat Charcot Marie Tooth Disease but has substantially no antibacterial activity.
1 . A method of treating Charcot-Marie-Tooth Disease (CMTD) in a human in need thereof, the method comprising systemically administering to the human a non-antibacterial tetracycline compound in an amount that is effective to treat CMTD, wherein the non-antibacterial tetracycline compound is selected from the group consisting of: 6-demethyl-6-deoxy-4-dedimethylaminotetracycline (CMT-3); 4-dedimethylaminodoxycycline (CMT-8); 9-amino-6-demethyl-6-deoxy-4-dedimethylaminotetracycline (CMT-308); 4-de(dimethylamino)-minocycline (CMT-10), and salts thereof,
wherein creatine monohydrate and/or dextrose are/is not administered.
2 . The method according to claim 1 , wherein the non-antibacterial tetracycline compound is administered in an amount that results in a plasma concentration which is about 0.01 μg/ml to about 1 μg/ml.
3 . The method according to claim 1 , wherein the non-antibacterial tetracycline compound is administered at a daily dose of about 10 mg/kg/day to about 100 mg/kg/day.
4 . The method according to claim 1 , wherein the non-antibacterial tetracycline compound is administered at a daily dose of about 1 mg/kg/day to about 20 mg/kg/day.
5 . The method according to claim 1 , wherein the non-antibacterial tetracycline compound is administered by controlled release over a 24-hour period.
6 . The method according to claim 1 , wherein the systemic administration is oral administration or intravenous injection.
7 . A method of treating Charcot-Marie-Tooth Disease (CMTD) in a human in need thereof, the method comprising systemically administering to the human a pharmaceutical composition comprising 6-demethyl-6-deoxy-4-dedimethylaminotetracycline (CMT-3) and salts thereof, in an amount that is effective to treat CMTD, wherein creatine monohydrate and/or dextrose are/is not administered.
8 . The method according to claim 7 , wherein CMT-3 is administered in an amount that results in a plasma concentration which is up to about 1.0 μg/ml.
9 . The method according to claim 7 , wherein CMT-3 is administered at a daily dose of up to about 1 to 20 mg/day.
10 . A method of treating Charcot-Marie-Tooth Disease (CMTD) in a human in need thereof, the method comprising systemically administering to the human a pharmaceutical composition comprising 4-dedimethylaminodoxycycline (CMT-8) and salts thereof, in an amount that is effective to treat CMTD, wherein creatine monohydrate and/or dextrose are/is not administered.
11 . A method of treating Charcot-Marie-Tooth Disease (CMTD) in a human in need thereof, the method comprising systemically administering to the human a pharmaceutical composition comprising 9-amino-6-demethyl-6-deoxy-4-dedimethylaminotetracycline (CMT-308) and salts thereof, in an amount that is effective to treat CMTD, wherein creatine monohydrate and/or dextrose are/is not administered.
12 . A method of treating Charcot-Marie-Tooth Disease (CMTD) in a human in need thereof, the method comprising administering systemically to the human an antibacterial tetracycline compound in an amount that is effective to treat CMTD, but has no antibacterial activity, wherein the antibacterial tetracycline compound is doxycycline, minocycline, tetracycline, oxytetracycline, chlortetracycline, demeclocycline, lymecycline or pharmaceutically acceptable salts thereof, wherein creatine monohydrate and/or dextrose are/is not administered.
13 . A method according to claim 12 , wherein the antibacterial tetracycline compound is administered in an amount that results in a plasma concentration which is less than approximately 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, 5%, 1% or 0.5% of MIC of the tetracycline compound for commonly occurring bacteria.
14 . A method according to claim 12 , wherein the antibacterial tetracycline compound is administered in an amount which is less than approximately 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, 5%, 1% or 0.5% of the minimum antibacterial dose.
15 . A method according to claim 12 , wherein the tetracycline compound is doxycycline administered in a daily amount of from about 10 to about 60 milligrams.
16 . A method according to claim 15 , wherein the doxycycline is administered orally twice a day in a dose of about 20 mg.
17 . A method according to claim 15 , wherein the doxycycline is administered by controlled release over a 24 hour period, in an amount of about 40 milligrams.
18 . A method according to claim 12 , wherein the tetracycline compound is doxycycline administered in an amount which results in a plasma concentration in the range of about 0.1 to about 0.8 μg/ml.